NCT00102128

Study to Examine the Safety and Effectiveness of Implanted Skeletal Muscle Cells (Cells Removed From the Thigh Muscle) Into Scarred Areas of Heart Muscle After Heart Attack.

Evaluation of Skeletal Myoblast Transplant for Treating Ischemic Heart Failure

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: —
• Sponsor: Genzyme, a Sanofi Company · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Study to examine the safety and effectiveness of implanted skeletal muscle cells (cells removed from the thigh muscle) into scarred areas of heart muscle after heart attack.

Conditions

• Ischemic Heart Failure
• Ischemic Heart Disease
• Ischemic Cardiomyopathy

Interventions

Type	Name	Description
DRUG	Cellular Therapy (Cultured Autologous Skeletal Myoblast Transplantation)

Timeline

• Start date: 2002-11-01
• Primary completion: 2007-04-01
• Completion: 2007-04-01
• First posted: 2005-01-24
• Last updated: 2015-05-22

Locations

28 sites across 6 countries: Belgium, France, Germany, Italy, Switzerland, United Kingdom